Journal: Biotechnology and Bioengineering

Article Title: Lassa hemorrhagic shock syndrome‐on‐a‐chip

doi: 10.1002/bit.27636

Figure Lengend Snippet: Lassa HS‐on‐a‐Chip. (a) Schematic diagram of the OrganoPlate used for perfusable microvessel culture, based on a 384 well plate interface on top and 96 microfluidic devices integrated in the bottom. (b) Each microfluidic device consists of a microvessel and an ECM channel separated by a phase‐guide, which prevents the gel from flowing into the adjacent channels. Every microfluidic structure is positioned underneath four adjacent wells; gel inlet (1), medium inlet (2), imaging/observation window (3), and medium outlet (4). (c) Method for microvasculature culture. Collagen gel is seeded into the ECM channel and polymerized, then HUVECs suspension is seeded into the perfusion channel. The perfusion is started by placing the plate on a tilted rocking platform with a rocking interval of 8 min, which creates a height difference resulting in gravity driven, continuous, and bidirectional perfusion flow. (d) HUVECs will then grow as a confluent monolayer against the collagen gel and channel walls, resulting in a microvessel with a perfusable lumen. ECM, extracellular matrix; HS, hemorrhagic shock; HUVEC, human umbilical vein endothelial cell [Color figure can be viewed at wileyonlinelibrary.com ]

Article Snippet: Microvascular channels were refreshed with 1, 10 and 50 μg/ml concentrations of Lassa VLPs (Lineage IV, LASVLP‐IV‐003; Zalgen Labs) diluted by Endothelial Cell Basal Medium 2 (0.2% serum) and incubated for 4 h. To measure vascular permeability, 20 μl HBSS was used to refresh the ECM channels.

Techniques: Imaging, Suspension

Journal: Biotechnology and Bioengineering

Article Title: Lassa hemorrhagic shock syndrome‐on‐a‐chip

doi: 10.1002/bit.27636

Figure Lengend Snippet: Lassa VLPs induced vascular permeability increase in the Lassa HS chip platform. (a) Apparent permeability ( P app ) of microvessels when exposed to Lassa VLPs for 4 h with the indicated concentrations (1, 10, 50 μg/ml). (b) P app of microvessels in response to 50 μg/ml Lassa VLPs at different time points (0.5, 2, 4, 6 h). (c) Time‐lapse fluorescence images of albumin perfusing in the negative control microvessel channel and diffusing from the Lassa VLPs treated microvessel to the ECM channel ( n = 12). HS, hemorrhagic shock; VLP, virus‐like particle [Color figure can be viewed at wileyonlinelibrary.com ]

Article Snippet: Microvascular channels were refreshed with 1, 10 and 50 μg/ml concentrations of Lassa VLPs (Lineage IV, LASVLP‐IV‐003; Zalgen Labs) diluted by Endothelial Cell Basal Medium 2 (0.2% serum) and incubated for 4 h. To measure vascular permeability, 20 μl HBSS was used to refresh the ECM channels.

Techniques: Permeability, Fluorescence, Negative Control, Virus

Journal: Biotechnology and Bioengineering

Article Title: Lassa hemorrhagic shock syndrome‐on‐a‐chip

doi: 10.1002/bit.27636

Figure Lengend Snippet: Microvascular dysfunction in the Lassa HS‐on‐a‐chip. Endothelial cells stained for VE‐cadherin (green) and F‐actin (red) after exposure to 50 μg/ml Lassa VLPs for 4 h. A relative increase in actin filament stress fiber formation was observed. HS, hemorrhagic shock; VLP, virus‐like particle [Color figure can be viewed at wileyonlinelibrary.com ]

Article Snippet: Microvascular channels were refreshed with 1, 10 and 50 μg/ml concentrations of Lassa VLPs (Lineage IV, LASVLP‐IV‐003; Zalgen Labs) diluted by Endothelial Cell Basal Medium 2 (0.2% serum) and incubated for 4 h. To measure vascular permeability, 20 μl HBSS was used to refresh the ECM channels.

Techniques: Staining, Virus

Journal: Biotechnology and Bioengineering

Article Title: Lassa hemorrhagic shock syndrome‐on‐a‐chip

doi: 10.1002/bit.27636

Figure Lengend Snippet: FX06 protects the vascular integrity in the Lassa HS chip platform. Microvessels ( n = 5 per condition) exposed to Lassa VLP (10 μg/ml) were treated with FX06 (1 mg/ml) for 4 h, followed by permeability assay. Fibrin‐derived peptide FX06 is able to suppress the Lassa‐induced vascular integrity loss. FX06 treated group is not significantly different from the NC. HS, hemorrhagic shock; NC, negative control; VLP, virus‐like particle

Article Snippet: Microvascular channels were refreshed with 1, 10 and 50 μg/ml concentrations of Lassa VLPs (Lineage IV, LASVLP‐IV‐003; Zalgen Labs) diluted by Endothelial Cell Basal Medium 2 (0.2% serum) and incubated for 4 h. To measure vascular permeability, 20 μl HBSS was used to refresh the ECM channels.

Techniques: Permeability, Derivative Assay, Negative Control, Virus